Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2006 1
2010 1
2012 1
2016 1
2017 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series.
Guisado-Vasco P, Arranz-Saez R, Canales M, Cánovas A, Garcia-Laraña J, García-Sanz R, Lopez A, López JL, Llanos M, Moraleda JM, Rodriguez J, Rayón C, Sabin P, Salar A, Marín-Niebla A, Morente M, Sánchez-Godoy P, Tomás JF, Muriel A, Abraira V, Piris MA, Garcia JF, Montalban C; Spanish Hodgkin Lymphoma Study Group. Guisado-Vasco P, et al. Leuk Lymphoma. 2012 May;53(5):812-9. doi: 10.3109/10428194.2011.635861. Epub 2012 Jan 31. Leuk Lymphoma. 2012. PMID: 22185637
Comments on the value International Prognostic Score (IPS), stage IV and age over 45 years, for the outcome of advanced Hodgkin lymphoma in chemotherapy containing adriamycin. The experience of the Spanish Hodgkin Lymphoma Study Group.
Guisado-Vasco P, Montalban C, García JF; Spanish Hodgkin Lymphoma Study Group. Guisado-Vasco P, et al. Br J Haematol. 2017 Jul;178(2):336-338. doi: 10.1111/bjh.14127. Epub 2016 May 2. Br J Haematol. 2017. PMID: 27135208 Free article. No abstract available.
A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma.
Sánchez-Espiridión B, Montalbán C, López A, Menárguez J, Sabín P, Ruiz-Marcellán C, Lopez A, Ramos R, Rodríguez J, Cánovas A, Camarero C, Canales M, Alves J, Arranz R, Acevedo A, Salar A, Serrano S, Bas A, Moraleda JM, Sánchez-Godoy P, Burgos F, Rayón C, Fresno MF, Laraña JG, García-Cosío M, Santonja C, López JL, Llanos M, Mollejo M, González-Carrero J, Marín A, Forteza J, García-Sanz R, Tomás JF, Morente MM, Piris MA, García JF; Spanish Hodgkin Lymphoma Study Group. Sánchez-Espiridión B, et al. Blood. 2010 Aug 26;116(8):e12-7. doi: 10.1182/blood-2010-02-270009. Epub 2010 May 17. Blood. 2010. PMID: 20479282 Free article. Clinical Trial.
Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma.
Sánchez-Aguilera A, Montalbán C, de la Cueva P, Sánchez-Verde L, Morente MM, García-Cosío M, García-Laraña J, Bellas C, Provencio M, Romagosa V, de Sevilla AF, Menárguez J, Sabín P, Mestre MJ, Méndez M, Fresno MF, Nicolás C, Piris MA, García JF; Spanish Hodgkin Lymphoma Study Group. Sánchez-Aguilera A, et al. Blood. 2006 Jul 15;108(2):662-8. doi: 10.1182/blood-2005-12-5125. Epub 2006 Mar 21. Blood. 2006. PMID: 16551964 Free article.
Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays.
García JF, Camacho FI, Morente M, Fraga M, Montalbán C, Alvaro T, Bellas C, Castaño A, Díez A, Flores T, Martin C, Martinez MA, Mazorra F, Menárguez J, Mestre MJ, Mollejo M, Sáez AI, Sánchez L, Piris MA; Spanish Hodgkin Lymphoma Study Group. García JF, et al. Blood. 2003 Jan 15;101(2):681-9. doi: 10.1182/blood-2002-04-1128. Epub 2002 Sep 12. Blood. 2003. PMID: 12393683 Free article.